360 results on '"Kupper, H."'
Search Results
2. OP0115 EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY
3. POS0365 ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
4. Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
5. Long-Term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-Radiographically Evident Axial Spondyloarthritis Who Experience a Flare
6. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE
7. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study
8. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
9. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
10. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
11. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
12. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis
13. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patientʼs perspective
14. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
15. Dexverapamil as resistance modifier in acute myeloid leukaemia
16. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma
17. Dexverapamil to overcome epirubicin resistance in advanced breast cancer
18. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
19. Therapeutics 2: OP62. EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) IN EUROPEAN CLINICAL PRACTICE: THE REACT TRIAL
20. Therapeutics 1: OP3. THE REACT TRIAL: EFFICACY EVALUATION OF ADALIMUMAB (HUMIRA®) IN PATIENTS SWITCHING FROM PRIOR BIOLOGIC DMARD THERAPIES
21. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
22. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate
23. Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
24. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
25. Efficacy and safety the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7)in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
26. Anwendung monoklonaler Antikörper in der Immunhistologie
27. CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL
28. Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS)
29. IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES
30. Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial
31. Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)
32. Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas
33. Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira (R)) treatment
34. Europe
35. THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA): strive registry
36. Charakterisierung von T-Zell-Subpopulationen durch CD-45 R- und direkt markierte CD 3-, CD 4- und CD 8-mAK
37. Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
38. Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate versus Methotrexate Alone
39. Effective Disease Control Following Up to 10 Years of Treatment with Adalimumab in Patients with Long-Standing Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Final 10-Year Results of the DE019 Trial
40. Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
41. INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES THAN WITH EITHER MONOTHERAPY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: 8-YEAR RESULTS OF AN OPEN-LABEL EXTENSION OF A PHASE 3 TRIAL
42. INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES IN PATIENTS WITH ADVANCED RHEUMATOID ARTHRITIS: ANALYSIS OF THE FINAL 10-YEAR RESULTS OF AN OPEN-LABEL EXTENSION OF A PHASE 3 TRAIL
43. Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results
44. Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial
45. Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
46. OP0065 Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
47. FRI0077 The Use of Ultrasound to Detect Residual Joint Inflammation in Patients with Rheumatoid Arthritis in Clinical Disease Remission
48. SAT0148 Similar Improvements in Quality of Sleep, Satisfaction with Medication and Sexual Impairment Among Rheumatoid Arthritis Patients Upon Initiation of Adalimumab in Combination with Two Doses of Methotrexate
49. FRI0022 Anemia is an Independent Predictor of Radiographic Damage Progression in Anti-TNF-Treated Rheumatoid Arthritis Patients from Two Large Phase III Trials
50. Impact of Age, Sex, Physical Function, Health-related Quality of Life, and Treatment with Adalimumab on Work Status and Work Productivity of Patients with Ankylosing Spondylitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.